PRIVIA HEALTH GROUP INC (PRVA) Fundamental Analysis & Valuation
NASDAQ:PRVA • US74276R1023
Current stock price
20.02 USD
-0.16 (-0.79%)
At close:
20.02 USD
0 (0%)
After Hours:
This PRVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PRVA Profitability Analysis
1.1 Basic Checks
- In the past year PRVA was profitable.
- In the past year PRVA had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: PRVA reported negative net income in multiple years.
- Each year in the past 5 years PRVA had a positive operating cash flow.
1.2 Ratios
- PRVA has a Return On Assets (1.67%) which is in line with its industry peers.
- Looking at the Return On Equity, with a value of 3.11%, PRVA is in line with its industry, outperforming 58.00% of the companies in the same industry.
- PRVA's Return On Invested Capital of 2.75% is in line compared to the rest of the industry. PRVA outperforms 45.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for PRVA is significantly below the industry average of 8.85%.
- The last Return On Invested Capital (2.75%) for PRVA is above the 3 year average (2.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.67% | ||
| ROE | 3.11% | ||
| ROIC | 2.75% |
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of PRVA (1.08%) is comparable to the rest of the industry.
- In the last couple of years the Profit Margin of PRVA has declined.
- PRVA has a Operating Margin (1.61%) which is in line with its industry peers.
- In the last couple of years the Operating Margin of PRVA has declined.
- PRVA has a Gross Margin of 9.87%. This is in the lower half of the industry: PRVA underperforms 75.00% of its industry peers.
- In the last couple of years the Gross Margin of PRVA has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.61% | ||
| PM (TTM) | 1.08% | ||
| GM | 9.87% |
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
2. PRVA Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
- The number of shares outstanding for PRVA has been increased compared to 1 year ago.
- PRVA has more shares outstanding than it did 5 years ago.
- PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 4.14 indicates that PRVA is not in any danger for bankruptcy at the moment.
- The Altman-Z score of PRVA (4.14) is better than 78.00% of its industry peers.
- There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.14 |
ROIC/WACC0.3
WACC9.08%
2.3 Liquidity
- A Current Ratio of 1.60 indicates that PRVA should not have too much problems paying its short term obligations.
- The Current ratio of PRVA (1.60) is better than 65.00% of its industry peers.
- A Quick Ratio of 1.60 indicates that PRVA should not have too much problems paying its short term obligations.
- With a decent Quick ratio value of 1.60, PRVA is doing good in the industry, outperforming 67.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 |
3. PRVA Growth Analysis
3.1 Past
- PRVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.55%, which is quite impressive.
- PRVA shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -9.93% yearly.
- Looking at the last year, PRVA shows a very strong growth in Revenue. The Revenue has grown by 22.26%.
- PRVA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.04% yearly.
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%
3.2 Future
- The Earnings Per Share is expected to grow by 57.20% on average over the next years. This is a very strong growth
- PRVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.44% yearly.
EPS Next Y106.06%
EPS Next 2Y65.53%
EPS Next 3Y57.2%
EPS Next 5YN/A
Revenue Next Year13.79%
Revenue Next 2Y12.12%
Revenue Next 3Y11.91%
Revenue Next 5Y10.44%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. PRVA Valuation Analysis
4.1 Price/Earnings Ratio
- PRVA is valuated quite expensively with a Price/Earnings ratio of 117.76.
- The rest of the industry has a similar Price/Earnings ratio as PRVA.
- Compared to an average S&P500 Price/Earnings ratio of 24.88, PRVA is valued quite expensively.
- Based on the Price/Forward Earnings ratio of 57.15, the valuation of PRVA can be described as expensive.
- PRVA's Price/Forward Earnings is on the same level as the industry average.
- PRVA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 117.76 | ||
| Fwd PE | 57.15 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PRVA indicates a slightly more expensive valuation: PRVA is more expensive than 60.00% of the companies listed in the same industry.
- PRVA's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. PRVA is cheaper than 73.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.15 | ||
| EV/EBITDA | 45.68 |
4.3 Compensation for Growth
- PRVA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- PRVA's earnings are expected to grow with 57.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.11
PEG (5Y)N/A
EPS Next 2Y65.53%
EPS Next 3Y57.2%
5. PRVA Dividend Analysis
5.1 Amount
- No dividends for PRVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PRVA Fundamentals: All Metrics, Ratios and Statistics
20.02
-0.16 (-0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)05-06 2026-05-06/bmo
Inst Owners99.61%
Inst Owner Change0.49%
Ins Owners1.85%
Ins Owner Change5.21%
Market Cap2.48B
Revenue(TTM)2.12B
Net Income(TTM)22.92M
Analysts84.29
Price Target32.15 (60.59%)
Short Float %2.15%
Short Ratio3.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)43.55%
Min EPS beat(2)-8.97%
Max EPS beat(2)96.08%
EPS beat(4)1
Avg EPS beat(4)-2.92%
Min EPS beat(4)-60.96%
Max EPS beat(4)96.08%
EPS beat(8)1
Avg EPS beat(8)-23.29%
EPS beat(12)3
Avg EPS beat(12)-1.19%
EPS beat(16)6
Avg EPS beat(16)61.33%
Revenue beat(2)1
Avg Revenue beat(2)5.86%
Min Revenue beat(2)-6.18%
Max Revenue beat(2)17.91%
Revenue beat(4)3
Avg Revenue beat(4)4.55%
Min Revenue beat(4)-6.18%
Max Revenue beat(4)17.91%
Revenue beat(8)7
Avg Revenue beat(8)4.33%
Revenue beat(12)10
Avg Revenue beat(12)3.07%
Revenue beat(16)10
Avg Revenue beat(16)-7.25%
PT rev (1m)0%
PT rev (3m)-0.08%
EPS NQ rev (1m)13.87%
EPS NQ rev (3m)13.87%
EPS NY rev (1m)8.83%
EPS NY rev (3m)9.32%
Revenue NQ rev (1m)-4.38%
Revenue NQ rev (3m)-31.33%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)-37.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 117.76 | ||
| Fwd PE | 57.15 | ||
| P/S | 1.17 | ||
| P/FCF | 15.15 | ||
| P/OCF | 15.15 | ||
| P/B | 3.36 | ||
| P/tB | 7.95 | ||
| EV/EBITDA | 45.68 |
EPS(TTM)0.17
EY0.85%
EPS(NY)0.35
Fwd EY1.75%
FCF(TTM)1.32
FCFY6.6%
OCF(TTM)1.32
OCFY6.6%
SpS17.16
BVpS5.96
TBVpS2.52
PEG (NY)1.11
PEG (5Y)N/A
Graham Number4.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.67% | ||
| ROE | 3.11% | ||
| ROCE | 4.27% | ||
| ROIC | 2.75% | ||
| ROICexc | 6.87% | ||
| ROICexgc | N/A | ||
| OM | 1.61% | ||
| PM (TTM) | 1.08% | ||
| GM | 9.87% | ||
| FCFM | 7.7% |
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
ROICexc(3y)6.14%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.37%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-16.37%
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
F-Score6
Asset Turnover1.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 136.39 | ||
| Cash Conversion | 370.18% | ||
| Profit Quality | 712.96% | ||
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z | 4.14 |
F-Score6
WACC9.08%
ROIC/WACC0.3
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)607.4%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
EPS Next Y106.06%
EPS Next 2Y65.53%
EPS Next 3Y57.2%
EPS Next 5YN/A
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%
Revenue Next Year13.79%
Revenue Next 2Y12.12%
Revenue Next 3Y11.91%
Revenue Next 5Y10.44%
EBIT growth 1Y101.6%
EBIT growth 3YN/A
EBIT growth 5Y6.15%
EBIT Next Year470.08%
EBIT Next 3Y100.08%
EBIT Next 5Y56.77%
FCF growth 1Y49.53%
FCF growth 3Y51.38%
FCF growth 5Y33.52%
OCF growth 1Y49.53%
OCF growth 3Y51.28%
OCF growth 5Y33.26%
PRIVIA HEALTH GROUP INC / PRVA Fundamental Analysis FAQ
What is the fundamental rating for PRVA stock?
ChartMill assigns a fundamental rating of 5 / 10 to PRVA.
Can you provide the valuation status for PRIVIA HEALTH GROUP INC?
ChartMill assigns a valuation rating of 3 / 10 to PRIVIA HEALTH GROUP INC (PRVA). This can be considered as Overvalued.
Can you provide the profitability details for PRIVIA HEALTH GROUP INC?
PRIVIA HEALTH GROUP INC (PRVA) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for PRVA stock?
The Price/Earnings (PE) ratio for PRIVIA HEALTH GROUP INC (PRVA) is 117.76 and the Price/Book (PB) ratio is 3.36.
Can you provide the financial health for PRVA stock?
The financial health rating of PRIVIA HEALTH GROUP INC (PRVA) is 7 / 10.